BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 10, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

CDC headquarters

US CDC endorses ACIP booster guidance, what’s next?

Jan. 6, 2022
By Mari Serebrov
Within hours of a Jan. 5 vote on COVID-19 boosters for adolescents, U.S. CDC Director Rochelle Walensky endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation that all adolescents aged 12-17 years should receive a booster dose five months after their primary series. The recommendation applies to the Pfizer Inc.-Biontech SE COVID-19 vaccine, as it’s the only one authorized in the U.S. for use in adolescents.
Read More

Regulatory actions for Jan. 6, 2022

Jan. 6, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allovir, Alphamab, CSPC, Nrx, Oncolyze, Oncotelic, Oncternal, Samsung, Simcere.
Read More

Other news to note for Jan. 6, 2022

Jan. 6, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, Alnylam, Biomea, Biomérieux, Cantabio, Clear Creek, Eisai, Exelixis, Genevant, ICER, Iconic, Liscure, Lqt, Novartis, Novo, Noxxon, Plus, Rain, Roche, Roivant.
Read More

In the clinic for Jan. 6, 2022

Jan. 6, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Angion, Annexon, Clover, Connect, Cytodyn, Edgewise, Exelixis, Humanigen, Inflarx, Inhibrx, Jazz, Longeveron, Moderna, Ocuphire, Prilenia, Samus, VBI, Verona,  Zosano.
Read More
Risk blocks, hand holding magnifier

Theranos saga leaves investors with hunger for transparency

Jan. 5, 2022
By Mark McCarty
The epic rise and fall of Elizabeth Holmes, founder of Theranos Inc., will preoccupy the world of business for decades to come, but this story has also left a large footprint in the world of clinical diagnostics. David Stein, CEO of Babson Diagnostics Inc., of Austin, Texas, told BioWorld that investors are a bit more wary than usual because of the Theranos saga, forcing test developers to be more rigorous in test development and more transparent with investors about a test.
Read More
Shipping container with flag of China

China med-tech exports declined in 2021 as imports increased

Jan. 5, 2022
By Zhang Mengying
China’s med-tech products exports declined in 2021 as manufacturing in other countries picked up, while med-tech imports to the country increased. In the first half of 2021, China’s med-tech exports amounted to $47.931 billion, a decrease of 23.1% year-on-year. But imports for the same period amounted to $24.392 billion, an increase of 25.2% year-on-year, according to med-tech data company Guangzhou Joinchain Big Data Technology Co. Ltd.
Read More
Teen receiving vaccine

ACIP on board with boosters for adolescents

Jan. 5, 2022
By Mari Serebrov
Once the CDC accepts the recommendation of its Advisory Committee on Immunization Practices (ACIP), the COVID-19 vaccine regimen, at least for the Pfizer Inc.-Biontech SE vaccine, will include a booster dose for everyone 12 and older. ACIP voted 13-1 at a Jan. 5 emergency meeting to recommend the booster dose for 12- to 17-year-olds at least five months after a primary series of the Pfizer vaccine.
Read More
COVID-19 research illustration

Biopharmas keep on keeping on, despite mounting omicron infections

Jan. 5, 2022
By Karen Carey
Just as the world appeared to be winning the battle against COVID-19, the rules of the game changed. Omicron and concerns about future variants flipped the board. Vaccines and monoclonal antibodies are attracting fresh scrutiny as SARS-CoV-2 evolves. Cases are climbing closer to the highest levels recorded since the pandemic began. Antivirals are aiming to fill treatment gaps, but whether they will or not is about as clear as the virus’ next move.
Read More

Regulatory actions for Jan. 5, 2022

Jan. 5, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AB Science, Abbvie, Abionyx, Adverum, Akeso, Amylyx, Ananda, Astrazeneca, Cstone, Cullinan, Everest, Iliad, Genprex, Immix, Jazz, Knight, Melt, Nordic, Novavax, Oryzon, Pfizer, PTC, Spero, Splisense, Verseau, Viridian.
Read More

Other news to note for Jan. 5, 2022

Jan. 5, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Actinium, Alloy, Ares, Aveo, Biorchestra, Biohaven, Biontech, Champions, Covis, Cue, Cyclenium, Dotbio, Elicera, Epicentrx, Eversana, F-star, Genentech, Immunicum, Insilico, Intellia, Intravacc, Junshi, Kyverna, Lixte, LG Chem, Mannkind, Mdimune, Merck KGaA, Mindset, McQuade, Nanotic, Nikang, Novartis, Owp, PCI, Peptilogics, Pfizer, Prism, Roche, SK, Spectrum, Suono, Thirona, Twist, Vuja, Zynerba.
Read More
Previous 1 2 … 146 147 148 149 150 151 152 153 154 … 553 554 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2026.
  • 3D rendering of an antibody drug conjugate

    ‘Target-high but uptake-defective’ state identified in ADC resistance

    BioWorld
    Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
  • Illustration of brain and brain waves, concept of focal seizure

    Hyperexcitability may be joint problem in epilepsy, dementia

    BioWorld
    The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing